Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R21 Clinical Trial Not Allowed)
ID: 343744Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for the "Advancing Methods for Safe, Noninvasive, Real-Time Assessment of Placenta Development and Function Across Pregnancy" through an R21 grant. This initiative aims to support innovative research focused on developing safe, real-time, non-invasive methods to assess placental health throughout pregnancy, with an emphasis on methodologies applicable from early gestation and risk assessments for pregnancy complications. The program encourages collaboration among diverse experts, particularly in obstetrics, and highlights the importance of high-risk, high-reward research approaches. Interested applicants can apply for a total funding ceiling of $275,000 over two years, with applications due by November 16, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-22-236.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, via the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) for the "Advancing Methods for Safe, Noninvasive, Real-Time Assessment of Placenta Development and Function Across Pregnancy." This R21 grant aims to support new and innovative research that enhances real-time assessment of human placental health throughout gestation using non-invasive techniques. Key priorities include developing methodologies that are applicable from early gestation and facilitating risk assessments for pregnancy complications. The announcement underscores a need for collaborations that incorporate diverse expertise, particularly in obstetrics, and emphasizes the importance of high-risk, high-reward approaches. Eligible applicants include various institutions (public, private, and foreign entities) with application deadlines set for 2023 and 2024, highlighting a total funding ceiling of $275,000 over two years. The FOA urges the integration of biostatistics consultants on clinical studies and encourages the sharing of research data to boost overall scientific impact. Successful applications will be judged on the significance, innovation, and thoroughness of their approach, aiming ultimately to enhance clinical management approaches for placental disorders, potentially transforming health outcomes in pregnancy.
    Similar Opportunities
    Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy" under the R01 grant mechanism, which does not allow clinical trials. This initiative aims to support the development and clinical validation of innovative, non-invasive methods to assess placental health throughout pregnancy, addressing critical issues such as preeclampsia and stillbirth. The funding is part of the Human Placenta Project and encourages applications from a diverse range of organizations, including educational institutions and community-based organizations, with no budget limits specified, although proposals should reflect actual project needs. Interested applicants must submit their proposals by November 5, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)" aimed at investigating the interactions between HIV, antiretroviral therapy (ART), and substance use during pregnancy. This initiative seeks to enhance understanding of placental health and its implications for maternal and fetal outcomes, particularly focusing on the pathophysiology of placental abnormalities in the context of substance misuse. The NIH plans to allocate up to $2 million for fiscal year 2025 to support 2-5 research project grants, with applications opening on October 15, 2024, and a submission deadline of November 15, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality" (NOFO PAR-24-059). This initiative aims to support multidisciplinary research focused on addressing the high rates of maternal morbidity and mortality in the United States, particularly among racial and ethnic minorities, socioeconomically disadvantaged groups, and underserved rural populations. The program encourages innovative intervention studies that evaluate healthcare factors affecting maternal health, with the goal of reducing disparities and improving outcomes across the continuum of care from prenatal to postpartum. Eligible applicants include a range of organizations, and awards can last up to five years, with budgets tailored to project needs. Interested parties can find more information and apply by visiting the NIH grants website, with the application deadline set for January 7, 2027.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    The Road to Prevention of Stillbirth Clinical Research Centers (UG1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Road to Prevention of Stillbirth – Clinical Research Centers" funding opportunity, aimed at establishing Research Centers within the Stillbirth Research Consortium. This initiative focuses on reducing the incidence of stillbirth in vulnerable populations through interdisciplinary research, with key objectives including the development of clinical tools, understanding mechanisms contributing to stillbirth, and enhancing maternal-fetal communication. The program emphasizes collaboration among diverse research teams and requires a Plan for Enhancing Diverse Perspectives and a Plan for Inclusion of People with Lived Experience. An estimated $4.3 million in direct costs is available, with awards expected to support 3-5 projects, each with a maximum budget of $860,000 annually for up to 5 years. Interested applicants must submit preliminary letters of intent and adhere to comprehensive submission guidelines by the closing date of November 1, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at developing novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. This initiative encourages diverse scientific research focused on improving screening technologies, therapeutic interventions, and preclinical testing, particularly for "high priority" genetic conditions that are not currently recommended for screening but could benefit from early identification and treatment. Eligible applicants include a wide range of organizations, such as educational institutions, community-based organizations, and tribal governments, with applications due by November 5, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.